Devalued and Distrusted (eBook)
136 Seiten
Wiley (Verlag)
978-1-118-51129-9 (ISBN)
JOHN L. LaMATTINA, PHD, retired as president of Pfizer's Global Research and Development in 2007, where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous honors and awards, including an Honorary Doctor of Science from the University of New Hampshire. Currently a Senior Partner with PureTech Ventures, he is the author of Drug Truths: Dispelling the Myths About Pharma R&D (Wiley).
ACKNOWLEDGMENTS ix
INTRODUCTION 1
CHAPTER 1 THE FOUR SECRETS THE DRUG COMPANIES DON'T WANT
YOU TO KNOW 4
Drug Companies Underestimate Dangerous Side Effects 5
Drug Companies Control Much of the Information Your Doctor Gets
10
You're Often Prescribed Drugs That You Don't Need
14
Drugs Target the Symptoms, Not the Cause 19
Conclusion 22
References 23
CHAPTER 2 WHAT HAS HAPPENED TO R&D PRODUCTIVITY? 25
Impact of Mergers on R&D Productivity 26
Heightened FDA Requirements for NDAs 34
Higher Hurdles Set by Payers 41
Conclusion 46
References 48
CHAPTER 3 KEY THERAPEUTIC AREAS FOR IMPROVING HEALTH 49
Cancer 51
Diseases of the Brain 54
Cardiovascular Disease (CVD) 60
Diabetes 63
Bacterial Infections 65
Conclusion 68
References 69
CHAPTER 4 IMPROVING R&D OUTPUT 71
The Views of Others 72
Pharma's Blockbuster Mentality Needs to Change 72
Can "Predictive Innovation" Lead to Greater Success
Rates? 76
Would Royalties Make Scientists More Productive? 78
Will Drug Repositioning Help Fill the R&D Pipeline? 80
Consultants Don't Always Have the Facts 82
Personal Views 84
Discovery Must Focus on Productivity 85
Does Size Help or Hinder R&D Productivity? 87
To Outsource or Not to Outsource? That's the Pharma
R&D Question 89
Big Pharma Early Research Collaborations 92
Conclusion 93
References 95
CHAPTER 5 RESTORING PHARMA'S IMAGE 96
Illegal Detailing of Drugs 97
Pharmaceutical Companies Should Drop TV Ads 98
The Need for Greater Transparency 100
How Committed Is Big Pharma to Rare Diseases? 102
Pharmaceutical Companies and Philanthropy 104
Pharma Needs to Have Its Scientists Tell Their Stories 105
Conclusion 106
References 107
CHAPTER 6 FINAL THOUGHTS 109
References 114
INDEX 115
"Oz should invite LaMattina back on his show. Since
LaMattina treats all concerns respectfully, Oz needn't worry
about feeling devalued or distrusted." (Barron's, 5
May 2014)
"This is an honest book by an insider who believes in the
basic good that the industry does." (The Quarterly
Review of Biology, 1 September 2013)
"Summing Up: Recommended. General
audiences." (Choice, 1 September 2013)
"For those more loosely associated or aspiring to work
with in it, I particularly recommend this book as a balanced and
informative read on the pressures the industry faces. It should
also provide the basis for more reasoned argument and forewarn
anyone else potentially ambushed by a TV show."
(ChemMedChem, 19 July 2013)
"That said, the suggestions made by LaMattina for
improvements in productivity and transparency are timely, and the
book makes interesting if unexciting reading."
(Chemistry & Industry, 1 June 2013)
"John LaMattina (ex-head of Pfizer's global R&D) has a
new book out about the industry, called href="http://www.amazon.com/gp/product/B00ANR91W8/ref=as_li_ss_tl?ie=UTF8&tag=lagniappe-20&linkCode=as2&camp=1789&creative=390957&creativeASIN=B00ANR91W8">Devalued
and Distrusted. He href="http://www.pharmalot.com/2012/12/repairing-a-broken-pharma-image-lamattina-explains/">tells
Pharmalot that he got the idea to write a sequel to his
earlier book, href="http://www.amazon.com/gp/product/0470393181/ref=as_li_ss_tl?ie=UTF8&tag=lagniappe-20&linkCode=as2&camp=1789&creative=390957&creativeASIN=0470393181">Drug
Truths, when he appeared on the "Dr. Oz" show."
(In The Pipeline, 1 December 2012)
" ... the book is laden with so many facts, critical
insights and pearls of wisdom that it deserves the attention of a
wide audience, from lay people to professionals in R&D,
medicine, government, business and mass media. Dr. LaMatina has
performed a public service by drawing on his broad experience to
clarify the issues and the many challenges that have to be faced if
progress in therapeutic molecular medicine is to continue, and to
illuminate the ongoing tensions that are bound to arise with ever
increasing risks and costs in pharma and biotech R&D,
never-perfect new medicines and constantly rising consumer
expectations and government involvement."--E J
Corey, Harvard University
Erscheint lt. Verlag | 12.12.2012 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
Medizin / Pharmazie ► Pharmazie | |
Naturwissenschaften ► Chemie | |
Technik | |
Wirtschaft | |
Schlagworte | Biochemie u. Chemische Biologie • Biochemistry (Chemical Biology) • Chemie • Chemistry • Drug Discovery & Development • Medical Science • Medizin • Pharmacology & Pharmaceutical Medicine • Pharmakologie u. Pharmazeutische Medizin • Pharmazeutische Industrie • Wirkstoffforschung u. -entwicklung |
ISBN-10 | 1-118-51129-8 / 1118511298 |
ISBN-13 | 978-1-118-51129-9 / 9781118511299 |
Haben Sie eine Frage zum Produkt? |
![PDF](/img/icon_pdf_big.jpg)
Größe: 8,6 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich